Buy These 2 Stocks Before They Jump Over 100%, Says Oppenheimer

InvestorPlace

Cassava Stock Could Jump More Than 200 Times

Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock is vastly undervalued. Source: Pavel Kapysh / Shutterstock.com Additionally, my calculations indicate that the shares could easily soar over 200x after the company’s Alzheimer’s treatment, simufilam, is approved by the FDA. Meanwhile, there’s evidence that strong support for the drug is building am